Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
04 August 2021 | Story Leonie Bolleurs | Photo Johan Barnard
Experimental farm
The Paradys Experimental Farm donated 428 bales of animal feed to farmers who lost veld in the Fauresmith and Tierpoort districts.

“I wish I had more to give.” These are the words of Johan Barnard, Junior Lecturer and manager on the Paradys Experimental Farm of the University of the Free State (UFS) after he donated the last of 428 bales of animal feed to a farmer from the Tierpoort area this morning (4 August 2021).

After large parts of the Paradys Experimental Farm were destroyed by veld fires three years ago and 24 famers came out to help fight the fire, Barnard believes in planting a surplus of food that would enable him to share with farmers in need. Last year, he donated bales of animal feed to farmers in the Hertzogville district whose veld was destroyed.

Sharing resources

More recently – less than a month ago – veld fires destroyed thousands of hectares of land in the Tierpoort and Fauresmith districts. Barnard, who helped to put out the fires and saw the destruction, decided to make the extra animal feed available to the farmers who needed feed for their animals.

Together with research and teaching and learning, the community is one of the university’s focus areas. “As a university, we are sharing our knowledge. The destruction brought about by the veld fires has created an opportunity where the university can also share its resources,” says Barnard.

When he made the decision to help, the feed was, however, still on the fields and had to be cut, processed, and baled. But where there is a will and a community that stand together, there is a way.

The farmers in the Koppieskraal district brought their tractors and machinery to cut, rake, and bale the sorghum and grass. BKB contributed fuel to cover the running costs of the tractors and machinery.

Once the animal feed was baled, Barnard contacted Jack Armour, operations manager at Free State Agriculture, who not only spread the word to farmers that animal feed was available, but also provided fuel to deliver the bales to the farms destroyed by fires. Since last week, volunteers have come to collect the animal feed and distribute it to the farmers.

Barnard, who believes it is difficult to put a price value on the animal feed provided by the university, says to the farmers who received it, the value of these bales is priceless.

A priceless gift

Besides the thousands of hectares of pasture destroyed during the raging fires, farmers also lost a significant number of sheep and cattle. When Leon Kruger, Lecturer in the Department of Animal Science, on the experimental farm, saw the devastation caused by the fires, he posted on Facebook that he was available to assist in treating the animals.

Together with two government veterinarians and a colleague from the Glen Agricultural College, Kruger drove hundreds of kilometres to farms in the south and southwestern Free State to help farmers treat animals affected by the fires.

He says they have treated more than 800 animals, including sheep and cattle. “We treated the animals one by one, administering antibiotics and pain medication, as well as ointment to the burned areas. This difficult ordeal was, however, a baptism of fire for all of us; we are not familiar with burn wounds. A friend in Australia helped to compile criteria to classify the different degrees of burn wounds and we treated the animals accordingly.”

“Seeing the suffering of the animals was one of the most difficult ordeals I had to experience,” states Kruger, who helped several farmers save their animals during this time where they have already lost so much.


News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept